Abstract Library

#4059 Evaluation of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR) and Systemic Immune–Inflammation Index (SII) as potential biomarkers in patients with sporadic pancreatic neuroendocrine tumors (pNET)

Introduction: Pancreatic neuroendocrine tumors (pNETs) are rare neoplasm in which the investigation of new biomarkers is essential. An elevated Neutrophile to Lymphocyte Ratio (NLR), Platelet to Lymphocyte Ratio (PLR) and Systemic Immune-Inflammation Index (SII) has been proposed as a negative prognostic factor in several neoplasms, but their role in pNET is unclear.

Conference:

Presenting Author: Minotta R

Authors: Minotta R, Liccardi A, Cannavale G, Benevento E, Di Iasi G,

Keywords: pancreatic neuroendocrine tumor, neuroendocrine, cancer, biomarker, inflammation,

#3246 Baseline albumin and neutrophil-to-lymphocyte ratio as predictive biomarkers of response to platinum-based therapy in patients with highly proliferative neuroendocrine carcinomas

Introduction: Neuroendocrine carcinomas (NECs) with ki-67/MIB1>55% show different responses to platinum-based therapy. Loss of Rb protein and KRAS mutation are markers of response, but it is unknown whether also clinical factors may have a predictive role.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Colombo E

Authors: Colombo E, Manca P, Prinzi N, Torchio M, Corti F,

Keywords: neuroendocrine carcinoma, albumin, neutrophil-to-lymphocyte ratio, neutropenia, platinum-based therapy, predictive biomarker, clinical biomarker, NECs,

#3107 Predicting response after [166Ho]-radioembolization in patients with neuroendocrine tumor liver metastases using neutrophil-to-lymphocyte and thrombocyte-to-lymphocyte ratios

Introduction: Response after treatment with [166Ho]-radioembolization is difficult to predict in patients with NET. Neutrophil-to-lymphocyte ratio (NLR) and thrombocyte-to-lymphocyte ratio (TLR) have been described as prognosticators for response.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ebbers S

Authors: Ebbers S, Brabander T, Tesselaar M, Hofland J, Barentsz M,

Keywords: PRRT, NET, neuroendocrine tumor, neuroendocrine neoplasm, lutetium-177-dotatate, radioembolization, holmium-166, objective response, NLR, TLR,

#2115 Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials

Introduction: NETs are extremely heterogeneous in nature. Despite recent advances, few biomarkers are available to consistently predict prognosis and optimize treatment selection.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Chan D, Yao J, Carnaghi C, Buzzoni R, Herbst F,

Keywords: Neuroendocrine tumors, neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, everolimus, RADIANT-3, RADIANT-4, systemic inflammation, prognosis,

#1893 Peripheral Blood Biomarkers of Systemic Inflammation May Be Prognostic in Metastatic Gastroenteropancreatic Neuroendocrine Tumour (GEPNET) Patients Following 177Lu-DOTATATE (LuTate)

Introduction: LuTate is a treatment for well-differentiated NETs with adequate somatostatin receptor expression. Prognostic biomarkers in this population are lacking. Neutrophil-to-lymphocyte ratio (NLR) is prognostic in the majority of solid tumours but is reported to have less value in indolent well-differentiated NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Hayes A, Hosking E, Thomas D, Sjoquist K, Chan D,

Keywords: prognostic, biomarker, PRRT, LuTate,